CFM
ABOS icon

Catalyst Funds Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Catalyst Funds Management’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$108K Buy
45,600
+16,000
+54% +$40.8K 0.02% 486
2025
Q4 		$62.5K Hold
29,600
– – 0.01% 322
2025
Q3 		$50.6K Buy
29,600
+9,900
+50% +$13.7K 0.01% 477
2025
Q2 		$22.9K Buy
+19,700
New +$21.2K 0.01% 421

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Catalyst Funds Management's ABOS Position: Q1 2026 in Review

Catalyst Funds Management increased its Acumen Pharmaceuticals (ABOS) stake by 54% in Q1 2026, buying an estimated $40.8K and bringing the position to 45,600 shares worth $108K. The position accounts for 0.02% of the portfolio, ranked #486.

Catalyst Funds Management first reported a position in ABOS in Q2 2025 and has held it in 4 quarters since. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • Catalyst Funds Management held 45,600 shares of Acumen Pharmaceuticals worth $108K as of Q1 2026.
  • Catalyst Funds Management bought 16,000 Acumen Pharmaceuticals shares in Q1 2026, an estimated $40.8K.
  • Acumen Pharmaceuticals made up 0.02% of Catalyst Funds Management's portfolio in Q1 2026, its #486 holding.
  • Catalyst Funds Management first reported a position in Acumen Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Catalyst Funds Management's 13F filing for Q1 2026, filed 11 May 2026.